Skip to content
glp1.howSign in

Supportive Health

HRT for women and GLP-1 medications: menopause, weight, and body composition

Menopause shifts where the body stores fat and how well it holds muscle, the same ground a GLP-1 works on, so hormone therapy often comes up. This guide explains what HRT is for women, who benefits, the 2025–2026 FDA label changes, and how HRT does and doesn't overlap with GLP-1 weight management.

By the glp1.how editorial teamReviewed 3 min read

Evidence-backed

Around menopause, your body starts storing more fat around the abdomen and holds on to muscle less easily, and your metabolism shifts too. That's the same ground a GLP-1 works on, so hormone therapy and GLP-1s often come up in the same conversation. They do different jobs, and it helps to know which does what.

What HRT is (for women)

Menopausal hormone therapy (MHT, often just "HRT") replaces the estrogen that falls at menopause. If you still have a uterus, it's usually paired with a progestogen to protect the uterine lining. It comes as pills, skin patches, gels and sprays. Its main job is treating menopausal symptoms. It isn't a weight treatment.

Who benefits

According to the North American Menopause Society's 2022 position statement, HRT is mainly used for:

  • moderate-to-severe menopausal symptoms: hot flashes and night sweats (vasomotor symptoms), and genitourinary symptoms like vaginal dryness
  • bone protection, because it helps prevent the faster bone loss of menopause.

The benefit–risk balance is most favorable when HRT is started near menopause, roughly before age 60 or within 10 years of your last period. The risks, including breast cancer and blood clots, depend on the type of hormones, how they're delivered, when you start, and your personal and family history, so the decision is individual and one to make with your clinician.

The US labels have also changed. In November 2025 the FDA said it would remove the boxed warnings about cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels, while keeping the endometrial-cancer boxed warning for systemic estrogen-alone products (FDA, November 10, 2025 (external link)). The first updated labels, for six products, were approved on February 12, 2026 (FDA (external link)). The label change doesn't remove the risks; they still depend on your age, history and the product.

The menopause–weight connection

After menopause, women tend to gain fat, especially visceral (deep abdominal) fat, and lose some muscle, and their metabolic profile gets less favorable. This is often when midlife women start thinking about a GLP-1.

Where HRT and GLP-1s meet

HRT is linked to less visceral fat, but it isn't a weight-loss treatment. In the OsteoLaus cohort, an observational study, current HRT users had lower visceral fat and BMI than never-users, and the difference faded after they stopped. HRT did not preserve muscle (Papadakis et al., Journal of Clinical Endocrinology & Metabolism, 2018, DOI (external link)). A prospective study of women in surgical menopause, WHAM, found HRT use made no difference to weight or body composition (Price et al., Journal of Clinical Endocrinology & Metabolism, 2023, DOI (external link)). HRT may nudge where fat sits, but it won't do a GLP-1's job.

A GLP-1 acts on weight and appetite directly. Some women use both under medical care: a GLP-1 for weight and HRT for symptoms. Evidence on the combination is thin. One retrospective Mayo Clinic study of 106 postmenopausal women on semaglutide found that the 16 also using HRT lost more weight at 12 months (16% vs 12% of body weight), but it was small and not randomized (Hurtado et al., Menopause, 2024, DOI (external link)).

Protect your muscle. GLP-1 weight loss can cost lean mass, and menopause already erodes it, so protein and resistance training matter even more (see why strength training matters on a GLP-1).

One more GLP-1 point: tirzepatide can make oral contraceptives less effective, according to its US label (Zepbound prescribing information (external link)). That's about contraception, not HRT, and it's covered in women's health on a GLP-1. If it applies to you, raise it with your clinician.

If both treatments are on the table, plan them together with your clinician. For the men's side and a broader view, see HRT for men and the HRT + GLP-1 overview.

Study findings above are attributed to their authors and were located via PubMed.

This is general education, not medical advice. Hormone therapy has real benefits and risks that depend on your individual history, so decide with your clinician.

hrtmenopausewomenhormone-therapybody-composition

Common questions

Questions people often ask about this topic.

  • Does HRT help with menopause weight gain?

    HRT is linked to somewhat less visceral (belly) fat in observational data, but it isn't a weight-loss treatment and doesn't preserve muscle. It mainly treats menopausal symptoms, so it may nudge where fat sits but won't do a GLP-1's job.

  • Can I take HRT and a GLP-1 at the same time?

    Some women do, under medical care: a GLP-1 for weight and HRT for menopausal symptoms, since they address different problems. Evidence on the combination is limited to small observational studies, so plan both with your clinician.

  • Who is a good candidate for menopausal HRT?

    Generally women with moderate-to-severe menopausal symptoms (like hot flashes) or a need for bone protection. The benefit–risk balance is most favorable when HRT starts near menopause (before about 60 or within 10 years). The decision depends on your personal and family history.

  • Does a GLP-1 affect birth control?

    Tirzepatide can make oral contraceptives less effective, according to its label. That's about contraception, not HRT, but worth knowing. If it applies to you, ask your clinician about backup or non-oral options.

Evidence

The sources behind this article, labeled by type and strength.

Supporting3

  • The 2022 hormone therapy position statement of The North American Menopause Society (external link)

    Menopause (The North American Menopause Society), 2022 · Clinical guideline · Strong evidence

    (2022)

    doi:10.1097/GME.0000000000002028

    Consensus position statement. Hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, and prevents bone loss and fracture. Risks differ by type, dose, duration, route, timing of initiation and whether a progestogen is used. Critically for this article's timing claim: the benefit-risk ratio is favorable for women under 60 or within 10 years of menopause onset without contraindications, and less favorable beyond that because of greater absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia. The guideline basis for the 'who benefits' and 'individualized decision' sections, which previously had no source.

  • Menopausal Hormone Therapy Is Associated With Reduced Total and Visceral Adiposity: The OsteoLaus Cohort (external link)

    Journal of Clinical Endocrinology & Metabolism, 2018 · Peer-reviewed study · Moderate evidence

    Papadakis GE, Hans D, Gonzalez Rodriguez E, et al. (2018) · J Clin Endocrinol Metab

    doi:10.1210/jc.2017-02449

    Cross-sectional cohort analysis (1,053 women): current MHT users had lower visceral fat and BMI than never-users, with benefits not preserved after stopping and no effect on lean mass - supports the article's 'nudges fat distribution, not a weight-loss drug' framing. Observational design, so causation is not established.

  • ZEPBOUND (tirzepatide) injection: prescribing information (external link)

    DailyMed (Eli Lilly label) · Clinical guideline · Strong evidence

    (2026)

    US prescribing information (revised 8/2026), sections 7.2 and 8.3: patients on oral hormonal contraceptives should switch to a non-oral method or add a barrier method for 4 weeks after initiation and after each dose escalation.

Mixed findings4

Revision history

Updated 4 times since Sep 2, 2026 · show changes
  1. v5

    Evidence sources 3 → 7

  2. v4

    Common questions revised

  3. v3

    Summary rewritten; Body revised

  4. v2

    Body revised

  5. v1

    Change tracking began

Related guides

  • Hormone replacement therapy (HRT) and GLP-1 medications: an overview · HRT and GLP-1s keep coming up together because the times people look at hormones (menopause in women, low testosterone in men) are also times of weight and body-composition change. This overview explains what each does, who benefits, what weight loss does to testosterone, and how to plan the two together.
  • Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps · Losing a lot of weight usually costs a small amount of bone, mostly at the hip, and GLP-1 weight loss is no exception. So far the fracture data are reassuring and the drug itself does not look like the main cause, but the long-term evidence is thin. Here's what the bone-density and fracture studies show, who should pay the most attention, and the levers that kept bone steady in trials: resistance and impact training, protein, calcium and vitamin D, and a well-timed bone scan.
  • How GLP-1 medications affect men vs. women: what the sex differences actually are · The same GLP-1 medication doesn't act quite the same in men and women. On average women lose more weight, report more side effects, and absorb more of the drug at the same body weight, differences driven partly by estrogen and testosterone. This guide covers what the research shows about sex differences in weight loss, tolerability, blood sugar and biology, and what it means for what you should expect.
  • Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching · For women, the biggest GLP-1 question is fertility. Tirzepatide can make the pill less reliable, weight loss can bring back ovulation you weren't expecting, and none of these drugs is safe in pregnancy, which is why "Ozempic babies" happen. This guide covers contraception and pregnancy planning, the PCOS trial evidence, protecting bone and muscle, the heart, and the menopause overlap.
  • HRT for men (testosterone) and GLP-1 medications: what the connection really is · Low testosterone and excess weight are linked, but the cause often runs from the weight to the testosterone, and that changes when testosterone therapy actually helps. This guide covers who benefits from TRT and why losing weight on a GLP-1 can raise testosterone on its own.
  • CPAP as the weight comes off: managing sleep apnea on a GLP-1 · Tirzepatide (Zepbound) roughly halved sleep apnea severity in the SURMOUNT-OSA trials, and 42 to 50% of participants reached the trial's definition of resolution. That still left many with apnea, and the trials never tested stopping CPAP for good. This guide covers why you shouldn't retire your machine on your own, how pressure and mask fit change as weight comes off, when and how a repeat sleep test happens, and how an OSA diagnosis affects Zepbound coverage (as of September 2026).

Related terms

  • GLP-1 · A gut hormone (glucagon-like peptide-1) that stimulates insulin release, slows digestion, and reduces appetite; the target of drugs like semaglutide and liraglutide.
  • Menopausal hormone therapy (MHT) · Estrogen, usually combined with a progestogen (when the uterus is present), used to relieve menopausal symptoms such as hot flashes and to protect bone. Often just called 'HRT.' It is associated with less visceral fat but is not a weight-loss treatment.
  • Hormone replacement therapy (HRT) · Treatment that replaces a hormone the body no longer produces in adequate amounts — most commonly estrogen (usually with a progestogen) for menopausal women, or testosterone for men with hypogonadism. It is not a weight-loss treatment and is separate from GLP-1 medications.
  • Progestogen · A hormone — natural progesterone or a synthetic progestin — given alongside estrogen in menopausal hormone therapy to protect the lining of the uterus.
  • Boxed warning · The FDA's strongest prescription-drug warning, set in a black-bordered box at the top of the label to flag a serious or life-threatening risk.
  • Visceral fat · Fat stored deep in the abdomen around the internal organs, which is more strongly tied to metabolic and cardiovascular risk than fat under the skin.
  • BMI · Body mass index: a weight-to-height ratio commonly used as a screening threshold for obesity and GLP-1 eligibility.
  • Semaglutide · A GLP-1 receptor agonist medication made by Novo Nordisk, sold under the brand names Ozempic (type 2 diabetes) and Wegovy (weight management), each as an injection or a pill.

Was this helpful?

Improve this page